Rlavie’s Industry News archive brings together articles about chemical identity, intermediates, synthetic planning, analytical evidence, sourcing considerations, and changes in pharmaceutical development. It is a topic-led reading hub rather than a product catalogue, giving each subject enough context to be considered on its own article page.
Recent examples examine AI-assisted isomer identification and product verification, the path from AI molecule design to reliable manufacturing, and the relationship between proposed PFAS restrictions and fluorinated intermediate supply chains. Each article reflects the date and context shown and should not be read as a product specification for a particular compound.
Use this index to open the topic most relevant to your work and to move among related articles. For a compound-specific question, continue to the appropriate product record or enquiry route and identify the exact material, rather than treating a news headline as evidence about an individual product.
Results posted in 2026 provide a timely reason to revisit darigabat’s disclosed chemistry. The public route uses 3,5-dichloropyridazin-4-amine (CAS 53180-76-0), while a same-formula positional isomer shows why CAS, structure and analytical identity must agree.
FDA’s 2025 darolutamide indication expansion provides a timely reason to examine two exact Rlavie catalog products disclosed in a public route—and the identity, tautomer and impurity controls that matter when sourcing them.
FDA’s approval of taletrectinib puts fresh attention on the public chemistry behind ROS1 inhibitors. We examine how CAS 13526-66-4 functions in a disclosed route and what buyers should verify when sourcing this dual-halogen heterocycle.
The EU’s 2026 provisional agreement on the Critical Medicines Act places supply resilience, diversification and manufacturing capacity at the center of critical-medicine policy. For API and intermediate buyers, the practical question is how early to qualify alternative routes...
Pralsetinib improved progression-free survival in the 2026 AcceleRET-Lung Phase 3 study, but infection findings and early termination require balanced interpretation. Public patents also highlight the importance of controlling a key chiral amine intermediate.
The proposed EU PFAS restriction is not yet final, but it is already reshaping due diligence for fluorinated pharmaceutical intermediates. Learn what suppliers and buyers should map across structures, process materials, equipment, documentation and change control.
AI can screen chemical records for isomer-related inconsistencies, but batch identity, stereochemical purity and biological performance still require analytical evidence.
Chemical purity alone cannot establish the quality of a chiral pharmaceutical intermediate. Learn how route design, stereoselective analysis, specifications, documentation and change control help preserve stereochemical integrity.
Nitrosamine control is most effective when it begins before the final API or drug product. This article examines how raw materials, intermediates, reagents, recovered solvents, route design and change control shape risk.
A certificate of analysis is essential, but it is not the whole quality story. Learn what buyers should verify about identity, methods, impurities, traceability and change control when sourcing pharmaceutical intermediates.
Follow the path from an AI-designed molecule to route validation, impurity control, analytical release, scale-up and reliable supply.
AI is expanding chemical-space exploration. See why diverse, functionalized heterocyclic building blocks remain central to medicinal chemistry.